Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Jeay S, Ferretti S, Holzer P, Fuchs J, Chapeau EA, Wartmann M, Sterker D, Romanet V, Murakami M, Kerr G, Durand EY, Gaulis S, Cortes-Cros M, Ruetz S, Stachyra TM, Kallen J, Furet P, W├╝rthner J, Guerreiro N, Halilovic E, Jullion A, Kauffmann A, Kuriakose E, Wiesmann M, Jensen MR, Hofmann F, Sellers WR.

Cancer Res. 2018 Nov 1;78(21):6257-6267. doi: 10.1158/0008-5472.CAN-18-0338. Epub 2018 Aug 22.

PMID:
30135191
2.

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma.

Hansen VL, Coleman M, Elkins S, Letzer JP, Levy MY, Seneviratne L, Rine J, White M, Kuriakose ET.

Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):400-407.e1. doi: 10.1016/j.clml.2018.03.002. Epub 2018 Mar 14.

3.

Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.

Bloudek L, Roy A, Kish JK, Siegel DS, Jagannath S, Globe D, Orloski L, Kuriakose ET.

J Manag Care Spec Pharm. 2016 Aug;22(8):991-1002. doi: 10.18553/jmcp.2016.22.8.991.

4.

Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.

Jagannath S, Roy A, Kish J, Lunacsek O, Globe D, Eaddy M, Kuriakose ET, Willey J, Butler-Bird S, Siegel D.

Expert Rev Hematol. 2016 Jul;9(7):707-17. doi: 10.1080/17474086.2016.1195254. Epub 2016 Jun 16.

PMID:
27291638
5.

Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.

Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, Silver RT, van Besien K.

Clin Lymphoma Myeloma Leuk. 2016 May;16(5):297-303. doi: 10.1016/j.clml.2016.02.004. Epub 2016 Feb 18.

PMID:
27025789
6.

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

Roy A, Kish JK, Bloudek L, Siegel DS, Jagannath S, Globe D, Kuriakose ET, Migliaccio-Walle K.

Am Health Drug Benefits. 2015 Jun;8(4):204-15.

7.

Comparison of reported outcomes with percutaneous versus surgical closure of ruptured sinus of Valsalva aneurysm.

Kuriakose EM, Bhatla P, McElhinney DB.

Am J Cardiol. 2015 Feb 1;115(3):392-8. doi: 10.1016/j.amjcard.2014.11.013. Epub 2014 Nov 13. Review.

PMID:
25488356
8.

JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug.

Kuriakose ET, Gjoni S, Wang YL, Baumann R, Jones AV, Cross NC, Silver RT.

Haematologica. 2013 Nov;98(11):e135-7. doi: 10.3324/haematol.2013.087742. No abstract available.

9.

Reaction of rat subcutaneous tissue to mineral trioxide aggregate and Portland cement: a secondary level biocompatibility test.

Karanth P, Manjunath MK; Roshni, Kuriakose ES.

J Indian Soc Pedod Prev Dent. 2013 Apr-Jun;31(2):74-81. doi: 10.4103/0970-4388.115698.

10.

Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Kuriakose E, Vandris K, Wang YL, Chow W, Jones AV, Christos P, Cross NC, Silver RT.

Haematologica. 2012 Apr;97(4):538-42. doi: 10.3324/haematol.2011.053348. Epub 2011 Nov 18.

11.

Corneal transplantation in scleral staphylomas.

Kuriakose ET.

Indian J Ophthalmol. 1981 Dec;29(4):411-3. No abstract available.

12.

Cataract after busulphan treatment.

Ravindranathan MP, Paul VJ, Kuriakose ET.

Br Med J. 1972 Jan 22;1(5794):218-9. No abstract available.

13.

Rare manifestations of leprosy.

Kuriakose ET.

J Indian Med Assoc. 1968 Jan 16;50(2):69 passim. No abstract available.

PMID:
5665598
14.

OCULOSPORIDIOSIS: RHINOSPORIDIOSIS OF THE EYE.

KURIAKOSE ET.

Br J Ophthalmol. 1963 Jun;47:346-9. No abstract available.

15.

Mooren's ulcer. Etiology and treatment.

KURIAKOSE ET.

Am J Ophthalmol. 1963 May;55:1064-9. No abstract available.

PMID:
13927487

Supplemental Content

Loading ...
Support Center